Business Services Industry
Zacks Buy List Highlights: The Goodyear Tire & Rubber Co., Unit Corporation, Caremark Rx, Inc., and Emerson Electric
Business Wire, Sept 16, 2005
CHICAGO -- Zacks.com releases another list of stocks that are currently members of the coveted Zacks #1 Rank (Strong Buy) List. The #1 Rank stocks highlighted today are The Goodyear Tire & Rubber Co. (NYSE:GT) and Unit Corporation (NYSE:UNT). Further, Zacks announced #2 Rankings (Buy) on two other widely held stocks: Caremark Rx, Inc. (NYSE:CMX) and Emerson Electric Co. (NYSE:EMR). To see the full Zacks #1 Rank (Strong Buy) List, or the rank for any other stock, visit: http://at.zacks.com/?id=88
Stocks ranked #1 (Strong Buy) by Zacks have produced an average annual return of 33% since inception in 1988. During the 2000-2002 bear market, Zacks #1 Rank stocks gained 43.8% while the S&P 500 tumbled 37.6%.
Related Results
Here is a synopsis of why GT and UNT have a Zacks Rank of 1. Note that a #1 Strong Buy rating is applied to only 5% of all the stocks Zacks ranks:
The Goodyear Tire & Rubber Co. (NYSE:GT) earnings estimates for the year ending December 2005 moved up 20 cents, or about 17%, from two months ago. In early August, the company announced second-quarter earnings results that surpassed the consensus estimate by 110% and topped the prior year result. The company noted that five of its businesses had record second quarter sales, and margins improved in its North American and European Union tire businesses.
Unit Corporation (NYSE:UNT) earnings estimates for the year ending December 2005 are above the two months ago levels by 50 cents, or approximately 16%. In late July, the company posted second-quarter earnings of 86 cents per share compared to 44 cents for the prior year. The result was almost 18% ahead of the consensus estimate. UNT mentioned that favorable commodity prices and industry conditions are producing great results and more growth opportunities.
Here is a synopsis of why CMX and EMR have a Zacks Rank of 2 (Buy). Note that a #2 Buy rating is applied to 15% of all the stocks ranked by Zacks:
Caremark Rx, Inc. (NYSE:CMX) posted second-quarter earnings of 47 cents per share in early August, beating last year's 30 cents and outperforming the consensus estimate by about 2%. The company mentioned that it continues to perform well both operationally and financially. CMX also raised its full year earnings guidance to a range of $1.95 to $1.97. Analysts have been increasing estimates as well. Current full year 2005 earnings estimates of $1.96 per share are above two months ago levels by three cents, or almost 2%.
Emerson Electric Co. (NYSE:EMR) reported fiscal third-quarter earnings of $1.00 per share, excluding an item. The result improved on last year's 81 cents and eclipsed the consensus estimate by approximately 5%. The company stated that its continued focus on strategic technology investments allows it to better meet its customers' needs, anywhere in the world. EMR increased its fiscal year 2005 expectations. Analysts are in agreement as evidenced by their upward revisions of earnings estimates for the year ending September 2005. Current estimates of $3.51 per share are approximately 1% above two months ago levels.
Truly taking advantage of the Zacks Rank requires the understanding of how it works. The free special report, "Zacks Rank Guide: Harnessing the Power of Earnings Estimate Revisions," provides an insightful background about this wealth-building tool. Download your free copy of the report now to prosper in the years to come by visiting http://at.zacks.com/?id=93.
About the Zacks Rank
For over 16 years, the Zacks Rank has proven that "Earnings estimate revisions are the most powerful force impacting stock prices." Since inception in 1988, #1 Rank stocks have generated an average annual return of 33%. During the 2000-2002 bear market, Zacks #1 Rank stocks gained 43.8%, while the S&P 500 tumbled 37.6%. Also note that the Zacks Rank system has just as many Strong Sell recommendations (Rank #5) as Strong Buy recommendations (Rank #1). Since 1988, Zacks Rank #5 stocks have underperformed the S&P 500 by 143.5% annually ( 4.9% vs. 12%). Thus, the Zacks Rank system allows investors to truly manage portfolio trading effectively.
Zacks "Profit from the Pros" e-mail newsletter offers continuous coverage of Zacks #1 Rank stocks and highlights those stocks poised to outperform the market. Subscribe to this free newsletter today by visiting http://at.zacks.com/?id=90.
The Zacks Rank, and all of its recommendations, is created by Zacks & Co., member NASD. Zacks.com displays the Zacks Rank with permission from Zacks & Co. on its web site for individual investors.
About Zacks
Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978 to compile, analyze, and distribute investment research to both institutional and individual investors. The guiding principle behind Zacks work is the belief that investment experts, such as brokerage analysts and investment newsletter writers, have superior knowledge about how to invest successfully. The goal is to unlock these pros' profitable insights for individual investors hard-pressed to find this valuable information in one source. A free subscription to "Profit from the Pros" weekly e-mail newsletter provides the best way to use these experts' insights for more profitable investing. Register for a free subscription to Profit from the Pros http://at.zacks.com/?id=91
- 5 Rules for Immediate Annuities
- Death in the Family: 12 Things to Do Now
- Dumbest Things You Do With Your Money
- 6 Online Networking Mistakes to Avoid
- 401(k) Mistakes to Avoid
- 5 Economic Scenarios to Keep You Up at Night
- The Real ‘Best Places to Retire’
- Best Credit Cards for You
- 12 Tough Questions to Ask Your Parents
- The Real ‘Best Colleges’
- Home Buyer Tax Credit: How to Cash In
- Why You Shouldn't Bash Cash
- 8 Phony 'Bargains' and Better Alternatives
- Danger: 3 Debit Card Scams to Avoid
- 6 Myths About Gas Mileage
- 29 Fees We Hate Most
- Quick and Easy Ways to Boost Returns
- Best Stocks to Buy Now
- Lower Your Taxes: 10 Moves to Make Now
- New Jobs: 8 Lessons from Real-Life Career Switchers
- The New Job Market: Who Wins and Who Loses?
- Health Care Reform's Public Option: Everything You Need to Know
- Volunteer Work When Unemployed: Should You Work for Free?
- Whose Recovery Is This?
- Long-Term-Care Insurance: 4 Biggest Risks to Avoid
Most Recent Business Articles
- Psyadon Pharmaceuticals, Inc. Announces Regulatory Milestones and the Initiation of a Clinical Trial of Ecopipam in Lesch-Nyhan Disease
- Emergence of “Femtomedicine” - New Frontier of Biomed Sciences - Reported at First Global Congress on Nano Medicine
- Research and Markets: Ethiopia Power Market Outlook to 2020
- Research and Markets: Orphan Drugs in Asia-Pacific: from Designation to Pricing, Funding & Market Access
- Research and Markets: Now You See It - TV Program Sponsorship & Product Placement in China
Most Recent Business Publications
Most Popular Business Articles
- 7 tips for effective listening: productive listening does not occur naturally. It requires hard work and practice - Back To Basics - effective listening is a crucial skill for internal auditors
- FHM Features Anna Benson, Baseball's Hottest Wife
- Building a DNA database: the federal government has just enacted two bills related to DNA. The first would drive the collection of DNA from all infants. The second would attempt to prevent the DNA that is collected from being misused
- America's most wanted j-o-b-s - 10 hottest employment opportunities
- Developmental sequence in small groups



